Figure 2.

Efficient GCV-dependent in vivo ablation of TK.007 transgenic iPSC-derived tumors. (a) Schematic depiction of the experimental design to test TK.007/GCV-mediated in vivo ablation. NSG mice were injected with 3 * 10⁶ iPSCs per flank and treated either immediately or 2–3 weeks later with three rounds of injections (blue arrows) performed on consecutive days with 50 mg/kg GCV or vehicle (NaCl). The tumor diameter was determined weekly until end-point analysis at week 6, which additionally included analysis of tumor histology. (b,c) Tumor volume, weekly determined with a caliper, at the indicated time points after injection of AAVS1 CAGs.TK-transgenic (b) or LV CAGs.TK-transduced cells (c) into NSG mice. GCV or NaCl was administered immediately upon iPSC injection. Each data point represents one teratoma. N = 4–8. Arrows indicate the time points of GCV/NaCl treatment. (d,e) Tumor volume at the indicated time points after injection of AAVS1 CAGs.TK-transgenic (d) or LV CAGs.TK-transduced (e) cells into NSG mice. GCV or NaCl was administered upon emergence of palpable tumors. Each data point represents one teratoma. N = 4–6. ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001.